ASP Isotopes Inc. (NASDAQ: ASPI) has made significant progress in its initiative to produce high-assay low enriched uranium (HALEU) in the United Kingdom. The company's UK subsidiary, Quantum Leap Energy Ltd (QLE Ltd), has entered into early engagement with the UK's regulators on new nuclear projects.
Following the completion of national security due diligence, the Department for Energy Security and Net Zero (DESNZ) confirmed QLE Ltd's eligibility to engage with the Office for Nuclear Regulation (ONR), the regulator for the nuclear industry in the UK. This development sets ASP Isotopes' subsidiary, Quantum Leap Energy, on the path to be the first commercial producer of HALEU in the UK.
The company is also preparing its nuclear site license and environmental permit applications and will work closely with DESNZ to obtain permission to enrich uranium for civil and commercial purposes. While definitive regulatory timelines have not been confirmed, internal estimates indicate a potential pathway to full licensing is achievable within this decade, subject to regulatory and site-specific progress.
In addition to regulatory progress, Rich Deakin has joined QLE Ltd as Senior Vice President and Managing Director, UK Strategic Projects. With over 35 years of experience across civil and defense nuclear sectors in the USA, UK, and Japan, Deakin's appointment brings significant industry expertise to the company.
This initiative further reinforces ASP Isotopes' global strategy to expand its enrichment capabilities across multiple regions and applications, supporting the transition to cleaner and more secure energy systems worldwide.
ASP Isotopes Inc. is an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries. The company employs proprietary technology, the Aerodynamic Separation Process (ASP Technology), with an initial focus on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
The company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass. There is a growing demand for isotopes such as silicon-28, molybdenum-100, molybdenum-98, zinc-68, ytterbium-176, nickel-64, chlorine-37, lithium-6, and uranium-235 for various emerging applications.
ASP Isotopes' expansion into the UK nuclear market and the addition of industry veteran Rich Deakin mark significant developments in the company's pursuit of producing HALEU and advancing its global enrichment capabilities. Following these announcements, the company's shares moved 0.36%, and are now trading at a price of $8.25. For the full picture, make sure to review ASP Isotopes's 8-K report.
